2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

909. Medical Education and Workforce Development: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research
PAPER

2852 Integrating immunology into hematology education: A curriculum development project

Shiliang Ge, MD, Eric Tseng, MD2, Hayley Merkeley, MD FRCPC3, Vicky Chan, MD, BSc4, Christopher Lemieux, MD5, Luke Chen, MD6, Christine Cserti-Gazdewich, MD, BSc, FRCPC7, Catharine M. Walsh, MD, MEd, PHD, FRCPC8, Jennifer Teichman, MD,MSc,FRCPC9
1 University of Toronto, Toronto, Ontario, Canada
2 St. Michael's Hospital, Toronto, Ontario, Canada
3 St. Paul's Hospital, Vancouver, British Columbia, Canada
4 Royal Columbian Hospital, Vancouver, Canada
5 CHU de Québec-Université Laval, Laval, Canada
6 Dalhousie University, Halifax, Canada
7 University Health Network, Toronto, Canada
8 The Hospital for Sick Children, Toronto, Canada
9 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

Introduction: With the advent of novel immune and cellular therapies over the last two decades, there is growing recognition that many classical and malignant hematologic disorders are rooted in immune dysregulation. However, no national consensus exists on which immunology topics should be incorporated into Canadian hematology training. We previously conducted a national needs assessment demonstrating that Canadian trainees, educators, and hematologists perceive current immunology teaching as insufficient and support the development of a structured curriculum. To address this gap, we used Delphi consensus methodology to identify and prioritize immunology curricular topics for inclusion in postgraduate hematology training.

Methods: Potential immunology curricular topics were identified through a literature review of previously published immunology curricular, solicited feedback from local experts, and input from Delphi panel members. A national panel of hematology experts was assembled through purposive sampling and included program directors, residency program committee members, and clinicians representing both classical and malignant hematology. In each Delphi round, panelists rated the priority of potential curricular topics using a 7-point scale (1=definitely exclude; 7=definitely include). After each round, responses were analyzed and qualitative feedback was used to refine topic wording. Revised topics were redistributed with anonymized group summary statistics (mean ± SD, median [range]) from the preceding round. Delphi rounds continued until consensus was achieved (Cronbach α ≥0.95) and a minimum of two rounds had been completed. Following achievement of consensus, topics rated ≥6/7 by at least 70% of respondents were considered for inclusion in the curriculum. Participants also ranked potential curriculum delivery formats.

Results: Eighteen stakeholders completed Round 1, representing five Canadian regions and a broad range of independent practice experience (range 3-19 years). Participants included current/former program directors (n=9, 50%), Residency Program Committee members (n=7, 39%), malignant hematologists (n=7, 39%), classical hematologists (n=9, 50%), and laboratory hematologists (n=2, 11%). Round 1 Cronbach's alpha was 0.96 (95% CI 0.93-0.98) and 8 of 18 topics (44%) met the consensus threshold. One additional topic suggested in Round 1 was added to Round 2. Twelve of the 18 participants completed Round 2, all of whom had participated in Round 1. Round 2 Cronbach’s alpha was 0.95 (95% CI 0.89-0.98), satisfying our pre-specified stopping criteria for the Delphi process. Despite panel attrition between rounds (18 to 12 respondents; 67% retention), the round-2 panel size remained within the range considered adequate for an expert panel and internal consistency across panelists was excellent, supporting the validity of the consensus.

Six of 19 topics (32%) achieved consensus in Round 2: T cell activation, co-stimulation and inhibition; therapies that target signal transduction pathways including B and T cell receptor signalling; B cell development and activation; laboratory immunology; principles of humoral immunity and different immunoglobulin isotypes; pathogenesis of hematology related autoimmune disease. The added topic, inhibitor development and immune tolerance induction in hemophilia, did not reach consensus. The lowest-rated topics were leukocyte migration into tissues (8% rating ≥6/7 on Likert scale), immunosuppressive tumour microenvironment (17%), immunosenescence (25%), and clonal hematopoiesis (33%). An immunology bootcamp was the preferred delivery format (first choice for 75% of respondents), followed by case-based learning (17%) and online learning modules (8%).

Conclusion: This national modified Delphi process met its pre-specified stopping criteria after two rounds, yielding expert consensus on six core immunology topics for Canadian hematology training. These centre on immunotherapies and the fundamentals of cellular and humoral immunology underpinning novel therapeutics, alongside laboratory immunology. Topics addressing tumour immunobiology and immunosenescence did not reach consensus and may suit elective content. These results, together with a clear preference for a bootcamp-style format supplemented by case-based teaching, will directly inform the development and pilot evaluation of an immunology curriculum, addressing a recognized educational gap for Canadian hematology trainees.

Shiliang Ge, MD: No relevant conflicts of interest to declare.